Covered recipient · General Payments record
SHUBHADA SHRIKANT SHRIKHANDE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$1,277.20
- Reported across 37 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $463.56 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Tempus AI, Inc | $170.86 | 4 |
| GENZYME CORPORATION | $76.17 | 2 |
| Janssen Biotech, Inc. | $64.78 | 2 |
| PFIZER INC. | $53.53 | 3 |
| Celgene Corporation | $36.40 | 2 |
| E.R. Squibb & Sons, L.L.C. | $24.02 | 1 |
| Incyte Corporation | $22.13 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $15.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Celgene Corporation | $17.46 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101147379 | CMS |
| Celgene Corporation | $18.94 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101147381 | CMS |
| E.R. Squibb & Sons, L.L.C. | $24.02 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101499471 | CMS |
| GENZYME CORPORATION | $40.15 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140014403 | CMS |
| GENZYME CORPORATION | $36.02 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140014471 | CMS |
| Incyte Corporation | $22.13 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141291260 | CMS |
| Janssen Biotech, Inc. | $25.17 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078688314 | CMS |
| Janssen Biotech, Inc. | $39.61 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078688898 | CMS |
| PFIZER INC. | $15.47 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131636936 | CMS |
| PFIZER INC. | $14.38 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131884805 | CMS |
| PFIZER INC. | $23.68 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131383501 | CMS |
| PUMA BIOTECHNOLOGY, INC. | $15.67 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1113859853 | CMS |
| Tempus AI, Inc | $59.84 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150174498 | CMS |
| Tempus AI, Inc | $7.54 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150174500 | CMS |
| Tempus AI, Inc | $91.83 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150174502 | CMS |
| Tempus AI, Inc | $11.65 | 12/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150174504 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.